Palvella Therapeutics, Inc. (PVLA) Payables (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Payables for 12 consecutive years, with $801000.0 as the latest value for Q3 2024.
- On a quarterly basis, Payables fell 71.56% to $801000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $801000.0, a 71.56% decrease, with the full-year FY2023 number at $936000.0, down 77.47% from a year prior.
- Payables was $801000.0 for Q3 2024 at Palvella Therapeutics, down from $969000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $19.7 million in Q3 2021 to a low of $801000.0 in Q3 2024.
- A 5-year average of $5.4 million and a median of $4.2 million in 2022 define the central range for Payables.
- Peak YoY movement for Payables: surged 366.88% in 2022, then plummeted 87.26% in 2024.
- Palvella Therapeutics' Payables stood at $7.7 million in 2020, then increased by 11.36% to $8.6 million in 2021, then plummeted by 51.75% to $4.2 million in 2022, then crashed by 77.47% to $936000.0 in 2023, then dropped by 14.42% to $801000.0 in 2024.
- Per Business Quant, the three most recent readings for PVLA's Payables are $801000.0 (Q3 2024), $969000.0 (Q2 2024), and $1.5 million (Q1 2024).